Medicines Co. (MDCO) Reports Q3 Loss of $0.70

Medicines Co. (NASDAQ: MDCO) reported Q3 EPS of ($0.70).

“During the third quarter of 2018, we continued to advance inclisiran through Phase III trials and other, key development steps,” said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. “We continue to be impressed by the blinded safety data emerging from the Phase III trials, and expect our clinical momentum to continue into 2019, moving toward anticipated clinical data readout early in the second half of 2019, as well as NDA and MAA submissions in late 2019 and early 2020, respectively.”

For earnings history and earnings-related data on Medicines Co. (MDCO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c